Summary Temozolomide (TMZ) has remained the chemotherapy of choice in patients with glioblastoma multiforme (GBM) primarily due to the lack of more effective drugs. Tumors, however, quickly develop resistance to this line of treatment creating a critical need for alternative approaches and strategies to resensitize the cells. Withaferin A (WA), a steroidal lactone derived from several genera of the Solanaceae plant family has previously demonstrated potent anti-cancer activity in multiple tumor models. Here, we examine the effects of WA against TMZ-resistant GBM cells as a monotherapy and in combination with TMZ. WA prevented GBM cell proliferation by dose-dependent G2/M cell cycle arrest and cell death through both intrinsic and extrinsic apoptotic pathways. This effect correlated with depletion of principle proteins of the Akt/mTOR and MAPK survival and proliferation pathways with diminished phosphorylation of Akt, mTOR, and p70 S6K but compensatory activation of ERK1/2. Depletion of tyrosine kinase cell surface receptors cMet, EGFR, and Her2 was also observed. WA demonstrated induction of N-acetyl-L-cysteine-repressible oxidative stress as measured directly and through a subsequent heat shock response with HSP32 and HSP70 upregulation and decreased HSF1. Finally, pretreatment of TMZ-resistant GBM cells with WA was associated with O6-methylguanine-DNA methyltransferase (MGMT) depletion which potentiated TMZmediated MGMT degradation. Combination treatment with both WA and TMZ resulted in resensitization of MGMTmediated TMZ-resistance but not resistance through mismatch repair mutations. These studies suggest great clinical potential for the utilization of WA in TMZ-resistant GBM as both a monotherapy and a resensitizer in combination with the standard chemotherapeutic agent TMZ.
Introduction
According to the American Cancer Society, over 23,000 new cases of brain and other nervous system tumors will be diagnosed in 2013 in the United States [1] . High grade gliomas, such as anaplastic astrocytoma and glioblastoma multiforme (GBM), account for approximately 38 % of primary brain tumors, and to date, treatment options have remained limited. Following optimal surgical debulking, radiation therapy alone has been shown to increase mean survival time of GBM patients from approximately 6 months to only 1 year [2] [3] [4] . Concomitant and adjuvant temozolomide (TMZ) with surgical debulking and radiotherapy represents the most effective approved treatment in GBM patients but still only yields a 2.5 month median survival benefit and 2 year survival rate of 26.5 % [5] [6] [7] [8] [9] .
The efficacy of TMZ is most frequently influenced by the methylation status of the MGMT (O6-methylguanine-DNA methyltransferase) gene promoter [10, 11] . In patient tumors with an unmethylated promoter, the MGMT protein is expressed and repairs the major O6-methylguanine cytotoxic DNA lesions caused by TMZ, essentially eliminating its anti-cancer efficacy [12, 13] . Fifty-five to sixty-five percent of glioma patients do not display tumor phenotypes favorable for treatment with TMZ, and those that do often quickly acquire resistance through acquisition of MGMT or mismatch repair (MMR) deficiencies that allow tolerance of the lesion [14] [15] [16] .
To date, experimental targeted therapies against proteins such as epidermal growth factor receptor (EGFR), mammalian target of rapamycin (mTOR), and PI3 kinase have yielded disappointing responses in GBM patients despite promising pre-clinical findings [14, 17] . Combined with the limitations of TMZ, this defines a critical need for improved diagnostic and therapeutic approaches for patients with both inherent and acquired TMZ resistance to either promote resensitization of the malignancy to TMZ or exploit unrelated vulnerabilities.
The 28-carbon steroidal lactone withaferin A (WA; Fig. 1a ), extracted from several genera of the Solanaceae plant family, has emerged as a promising anti-cancer chemotherapeutic agent with thiol-reactive and oxidative properties that exploit redox alterations in cancer cells [18] [19] [20] [21] [22] [23] . As such, it has demonstrated the ability to modulate many pathways involved in promoting cancer progression including specific proteins like heat shock protein (HSP) 90, Akt, NFkappaB, and the estrogen receptor (ER) [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] . Promising anti-tumor efficacy has been observed in prostate, thyroid, breast, melanoma, ovarian, cervical, and brain cancer models [19, 32, [35] [36] [37] [38] [39] [40] .
Here, we follow-up on our previous findings outlining the efficacy of WA in TMZ-sensitive glioblastoma cells lines to demonstrate its potential role as a novel therapeutic option against resistant tumors as both a single agent therapy and a TMZ-resensitizer through MGMT modulation.
Materials and methods
Cell culture and general reagents U87, U251, and T98G glioblastoma multiforme cell lines of human origin were grown in Dulbecco's modified Eagle's medium (DMEM #11995-065; Gibco, Grand Island, NY) supplemented with 10 % fetal bovine serum (FBS; SigmaAldrich, St. Louis, MO) and 1 % penicillin/streptomycin (Sigma-Aldrich, St. Louis, MO) in a 37°C humidified atmosphere of 5 % CO 2 in air. An additional human GBM cell line, U138, was maintained in equivalent media additionally supplemented with 2 % L-glutamine (200 mM; Sigma-Aldrich), 1 % MEM-vitamin (100×; Hyclone, Logan, UT), and 1 % MEM nonessential amino acids (Sigma Aldrich). The TMZ resistant cells U87TMZ and U251TMZ were derived as previously described via TMZ dose escalation from the parental U87 and U251 cells, respectively [41] .
TMZ was generously provided by the NCI Developmental Therapeutics Program (Bethesda, MD) and was stored as a 100 mM stock solution in DMSO at −80°C. Withaferin A (99 % pure by HPLC) was extracted, isolated, and stored as a 20 mM stock solution in DMSO at −80°C as previously described [42] . Propidium iodide (PI), RNase, N-acetyl-L-cysteine (NAC), protease inhibitor cocktail, and MEK inhibitor PD98059 were acquired from Sigma-Aldrich (St. Louis, MO). Annexin V-FITC was obtained from BD Biosciences (San Diego, CA). Caspase 8 inhibitor Z-IETD-FMK and caspase 9 inhibitor Z-LEHD-FMK were obtained from R&D Systems (Minneapolis, MN).
MTS assay
To determine the IC 50 values of WA, all cell lines were seeded in 96-well plates at a density of 2,500 cells/well, treated with 0.025-3 μM WA, and incubated for 72 h. Cell number and viability were quantified by the colorometric CellTiter96 Aqueous MTS assay (Promega, Fitchburg, WI) at 490 nm on a BioTek Synergy 2 plate reader (BioTek, Winooski, VT) as per the manufacturer's instructions.
To assess combinational effects of WA and TMZ, cells were plated in 75 cm 2 flasks and allowed to grow overnight. Cells were treated with 0.5-2 μM WA and harvested at 24, 48, and 72 h post-treatment (60-80 % confluency) for seeding in 96-well plates at densities of 500-10,000 cells/well. Following a 6 h incubation period, 10-50 μM and 100-500 μM TMZ were added to each well of the TMZ-sensitive and TMZ-resistant cells, respectively. After 48-144 h, cell number and viability were quantified by the MTS assay as described above.
CellTiter-Glo luminescent assay
To circumvent the auto-reductive potential of NAC that interferes with the MTS assay reagent, studies evaluating combination treatment with NAC and WA were completed with the CellTiter-Glo luminescent assay (Promega, Fitchburg, WI) measuring cell viability by adenosine triphosphate (ATP) levels. U251TMZ and U87TMZ cells were seeded at a density of 2,500 cells/well in white-chambered 96-well plates and allowed to incubate for 6 h before treatment with 1-5 mM NAC. After 1 h, 0.5-6 μM WA was added to each well. After 72 h, assay reagent was prepared and added as per the manufacturer's instructions, and the plates were evaluated on the BioTek Synergy 2 plate reader.
Cell cycle analysis U251TMZ and U87TMZ cells were plated and allowed to grow overnight to 30-50 % confluency. Cells were treated with 0.125-4 μM WA for 24 h. Cells were then collected, resuspended in 0.43 mL of 4°C 1× PBS followed by 1 mL of −20°C ethanol, and maintained at −20°C for a minimum of 24 h. Finally, cells were then pelleted by centrifugation, resuspended in 1× PBS with 40 μg/mL PI and 100 μg/mL RNase, and incubated at 37°C for 30 min before analysis by flow cytometry (BD LSRII; Becton Dickinson, San Diego, CA). Data analysis included only singlet living cells not displaying DNA fragmentation.
Apoptosis studies Cells were plated as described for cell cycle analysis, treated with 1-6 μM WA, and pre-treated for 1 h with 5 mM NAC where indicated. After 24 h, cells were collected and washed once with Annexin binding buffer as previously described [34] . Staining phosphatidylserine on the outer leaflet of the cell membranes on apoptotic cells with Annexin V-FITC and DNA staining by PI in necrotic and late apoptotic cells was performed to assess WA-induced cell death. Cells were stained with both compounds according to the manufacturer's instructions (BD Biosciences, San Diego, CA) for 15 min at 4°C and washed twice with Annexin binding buffer. Cells were resuspended in buffer and immediately analyzed by flow cytometry on the BD LSRII.
Immunoblotting
Cells were plated in the manner outlined for cell cycle analysis and treated with 0.5-5 μM WA. Where indicated, cells were either pre-treated with 5 mM NAC, 50 μM PD98059, 50 μM Z-IETD-FMK, or 50 μM Z-LEHD-FMK for 1 h or post-treated with 100-300 μM TMZ 24 h after WA. After 24-48 h, proteins were collected in lysis buffer (40 mM HEPES, 2 mM EDTA, 10 mM sodium pyrophosphate decahydrate, 10 mM β-glycerophosphate disodium salt pentahydrate, 1 % Triton X-100 supplemented with 100 μM phenylmethylsulfonyl fluoride, 1 mM Na 3 VO 4 , and 2 μL/mL protease inhibitor cocktail), quantified, separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and electrotransfered onto a Hybond nitrocellulose membrane as previously described in Samadi et al. [43] . Ten to eighty micrograms of protein sample was utilized per lane. Actin levels were used to ensure equal loading and transfer of proteins. All studies were repeated for accuracy. Primary rabbit antibodies against MGMT (#2739; 1:1500), MSH2 (#2017; 1:1000), and MSH6 (#3996; 1:1000) and primary mouse antibody against MLH1 (#3515; 1:1000) were acquired from Cell Signaling Technology (Beverly, MA). Primary mouse antibody against p-H2A.X (Ser139; #613401; 1:1000) was purchased from Biolegend (San Diego, CA). Additional primary and secondary antibodies were utilized as previously described at dilutions ranging from 1:250-1:5000 to 1:5000-1:20000, respectively [34] .
Evaluation of reactive oxygen species
The accumulation of intracellular peroxide-type reactive oxygen species (ROS) in U251TMZ and U87TMZ cells was determined using the general oxidative stress indicator CM-H 2 DCFDA (Molecular Probes, Grand Island, NY) that fluoresces upon oxidation. Cells were incubated at 37°C in 1× dPBS containing 20 μM CM-H 2 DCFDA for 1 h to allow for indicator preloading and plated in 96-well plates in phenol red-free DMEM at 20,000 cells/well. After 30 min, 1-5 μM WA and/or 5 mM NAC was added to the wells. Fluorescence was assessed on the BioTek Synergy 2 3 h post-treatment with excitation and emission filters of 485 nm and 528 nm, respectively.
Statistical analysis
GraphPad Prism 6 (version 6.02; GraphPad Inc., San Diego, CA) was used to generate best-fit non-linear sigmoidal dose response curves for IC 50 
Results

Characterization of TMZ resistant cell lines
U251 and U87 resistant sub-lines (U251TMZ and U87TMZ) were generated by exposing parental lines to increasing concentrations (30-300 μM) of TMZ over an 8-week period, pooling the resulting colonies, and confirming resistance as previously described [41] . Reduced TMZ effectiveness in established lines T98G and U138 has been previously confirmed [44] . Characterization of these cell lines demonstrated the absence of MGMT and the presence of mismatch repair proteins MLH1, MSH2, and MSH6 in parental U251 and U87 cells (Fig. 1b) . MGMT expression was observed in U251TMZ, T98G, and U138 cells but not U87TMZ. Compared to parental U87 cells, U87TMZ displayed lower levels of all three MMR proteins screened, suggesting the mechanism of U87TMZ resistance is due to heterogeneic deletion or mutation of these proteins.
Diminished cell proliferation and viability following withaferin A exposure
To evaluate the general cytotoxic effect of withaferin A, parental and resistant glioblastoma cells were treated with increasing concentrations of WA (0.025-3 μM) for 72 h with resulting cell number and viability determined by MTS assay (Fig. 1c) . WA dose escalation reduced cell proliferation and viability. By GraphPad analysis, the IC 50 values of TMZ resistant sub-lines U251TMZ and U87TMZ were lower compared to parental lines, demonstrating increased efficacy. IC 50 values were determined to be 0.766±0.045 μM, 0.357± 0.019 μM, 1.050±0.062 μM, 0.657±0.134 μM, 1.027± 0.105 μM, and 0.610±0.279 μM for U251, U251TMZ, U87, U87TMZ, T98G, and U138 cells, respectively.
Induction of G2/M cell cycle arrest by withaferin A in a dose-dependent manner Distribution of phases of the cell cycle was assessed by flow cytometry at 24 h. Consistent with the anti-proliferative effects seen in the MTS assays, WA treatment induced G2/M phase accumulation of U251TMZ and U87TMZ cells in a dosedependent manner, demonstrating a key cellular response to WA exposure. WA induced a dose-dependent shift in cell cycle arrest from the G0/G1 checkpoint to G2/M arrest with minimal change in the percentage of cells in S phase (Fig. 2a) . Maximal shift to G2/M arrest above baseline was observed at 1.5 μM in U87TMZ cells (17.8 % G2/M in controls increasing to 42.5 % with treatment; p=0.0001) and 2 μM in U251TMZ cells (43.1 % baseline to 72.3 % with treatment; p=0.0001) (Fig. 2b) . Doses above this level demonstrated diminished deviation from control with a return to higher G0/G1 and lower G2/M but also increased DNA fragmentation observed in the sub-G0/G1 region (data not presented).
Additionally, cyclin B 1 , a protein that displays G2/M phase-specific elevation, was evaluated by Western blotting to provide molecular confirmation of increases in G2/M cell cycle arrest. At 24 h, dose-dependent induction of cyclin B 1 was observed in both U87TMZ and U251TMZ cells with maximum expression levels observed at 1 μM and 2.5 μM WA, respectively, corresponding with flow cytometry findings (Fig. 2c) . Cyclin B 1 levels displayed similar peak expression levels at 48 h but with a more blunted response.
Withaferin A induces cell death through both the intrinsic and extrinsic apoptotic pathways PI and Annexin V-FITC dual staining analysis with flow cytometry was used to further characterize the antiproliferative effects of WA by assessing levels of apoptosis and necrosis following drug exposure. After 24 h of 1-3 μM WA, U87TMZ and U251TMZ cells demonstrated increases in Annexin V-only staining representative of early apoptotic processes with increases in dual staining representative of late apoptosis present at higher concentrations (2-6 μM) (Fig. 3a  and b ). U87TMZ cells alone appear to also show mild increases in levels of necrosis with WA exposure as demonstrated by staining with PI only. Total positive staining of control U87TMZ and U251TMZ cells was 8.2 % and 4.0 % but increased to 45.5 % (p = 0.01: 14.7 % early apoptosis; 23.0 % late apoptosis; 7.7 % necrosis) and 17.1 % (p= 0.0004: 9.1 % early apoptosis; 6.9 % late apoptosis; 1.0 % necrosis) with 2 μM WA, respectively. Six micromolar WA elevated total cell death to 80.0 % for U87TMZ (p<0.0001: 4.9 % early apoptosis; 62.6 % late apoptosis; 12.5 % necrosis) and 51.8 % for U251TMZ cells (p<0.0001: 4.0 % early apoptosis; 44.6 % late apoptosis; 3.1 % necrosis).
Molecular confirmation of an apoptotic response was conducted by Western blotting for cleaved and/or total levels of the following proteins: extrinsic procaspase 8, mitochondrial/ intrinsic procaspase 9, effector procaspases 3 and 7, and downstream poly(ADP-ribose) polymerase (PARP) cleavage (Fig. 3c) . At 24 h, increasing concentrations of WA resulted in progressively decreased levels of all procaspases and PARP, suggesting both intrinsic and extrinsic routes of apoptotic cell death. Maximum levels of cleaved caspase 8 were observed at 1-2.5 μM WA for U251TMZ and 0.5-1 μM WA for U87TMZ while highest levels for cleaved caspases 3 and 7 were observed at 5 μM WA for U251TMZ and 1-2.5 μM WA for U87TMZ. PARP cleavage increased up to 5 μM in both cell lines, the maximum concentration utilized, and suggests that the absence of cleaved caspases despite depletion of the procaspase form at high WA concentrations can be explained by a time-dependent nature of caspase signaling in which the To further evaluate the nature of the intrinsic and extrinsic apoptotic processing in WA-induced cytotoxicity, U251TMZ cells were pretreated with 50 μM of either caspase 8 inhibitor Z-IETD-FMK or caspase 9 inhibitor Z-LEHD-FMK for 1 h followed by 2.5 μM WA for 24 h. Pretreatment with both inhibitors resulted in a return to baseline for both cleaved caspase 3 and PARP levels and decreased amounts of cleaved caspase 7 compared to WA alone (Fig. 3d) . Inhibitors alone resulted in negligible changes. These data support that cytotoxicity at WA concentrations above IC 5 0 involves induction of intrinsically-and extrinsically-mediated apoptosis in the GBM cell lines tested.
Withaferin A modulates the Akt/mTOR and MAPK pathways Proteins in and related to the Akt/mTOR and mitogenactivated protein kinase (MAPK) pathways are key to proliferation and survival of GBM cells and other cancers [17] . These proteins were evaluated by Western blotting at 24-48 h post-treatment in U251TMZ and U87TMZ cells in order to evaluate WA activity against total and phosphorylated protein levels as a potential mechanism for the anti-proliferative effects observed (Fig. 4a) . At 24 h, total levels of Akt and increasing WA concentration. U251TMZ and U87TMZ cells demonstrated optimal concentrations for caspase cleavage with highest levels of PARP cleavage observed in both lines at 5 μM WA. d U251TMZ cells were pretreated with 50 μM of either caspase 8 inhibitor Z-IETD-FMK or caspase 9 inhibitor Z-LEHD-FMK for 1 h followed by 2.5 μM WA for 24 h to determine if WA-driven apoptosis was intrinsically or extrinsically mediated. Inhibition of both caspase 8 and 9 reduced WA-induced cleavage of caspases 3 and 7 as well as PARP mTOR were decreased between~1 and 5 μM WA with minimal changes occurring in total p70 S6 kinase (S6K) in both cells lines. However, activation of each protein via phosphorylation (p-Akt Ser473, p-mTOR Ser2448, and p-p70 S6K Thr389) was similarly reduced over this range. Phosphorylation at Thr412 of the nuclear isoform of p70 S6K, p85 S6K, was also reduced with increasing WA concentration (data not shown). These effects were observed through the 48 h timepoint and demonstrate an inhibitory effect of WA on the Akt/mTOR growth pathway. Additionally, phosphorylation (Thr172) of AMPKα, the catalytic subunit of a negative regulator of the Akt/mTOR pathway that responds to cellular and MAPK pathways as well as common surface tyrosine kinase receptors were evaluated by immunoblotting for total levels and activation by phosphorylation following treatment with WA at 24-48 h in U251TMZ and U87TMZ cells. Total levels of specific proteins in both pathways were decreased, but reduction of protein activation was only observed in the PI3K/Akt/MAPK pathway whereas phosphorylation of Raf-1 and ERK1/2 was increased. b To determine the nature of MAPK pathway activation, U251TMZ and U87TMZ cells were pretreated with 50 μM of the MEK inhibitor PD98059 for 1 h followed by 2.5 μM WA for 6 h or 24 h. PD98059 increased ERK1/2 phosphorylation but reduced WAinduced phosphorylation of ERK1/2 in a time-dependent manner. WA alone induced caspase 3 and PARP cleavage in both cell lines in a timedependent manner that was increased when combined with MEK inhibitor. This demonstrates that MAPK pathway activation with WA was acting in a pro-survival signal rather than contributing to apoptosis stressors, was increased with WA treatment, peaking at 1 μM in U251TMZ cells (Online Resource 1). Despite depletion of total levels of the downstream tumor suppressor TSC2, phosphorylation at Thr1462 was enhanced or maintained at all WA concentrations tested in U251TMZ cells. In contrast to previous observations in parental U87 cells [34] , total and phospho-levels of AMPKα were decreased in U87TMZ cells despite maintenance of p-TSC2 levels (Online Resource 1). The MAPKKK Raf-1 and the MAPK ERK2 were assessed to evaluate the effects of WA on the primary proliferative MAPK pathway (Fig. 4a) . Total Raf-1 levels decreased at 2.5-5 μM in both U251TMZ and U87TMZ cells, however, activating phosphorylation of the protein at Ser338 increased over the same concentration range. Downstream, minimal changes were observed in total ERK2 levels, but phosphorylation of ERK1/2 (Thr202/Tyr204) was notably increased in a dose-dependent manner in both cell lines with a maximum level achieved at 2.5 μM WA in each at both 24 h and 48 h. Given that phosphorylation of MAPK proteins is typical of a pro-survival response yet WA instead induces apoptosis in GBM cells, the MAPK pathway was further explored to determine if its activation was necessary for the induction of apoptosis or simply a compensatory pro-survival response. U251TMZ and U87TMZ cells were pretreated with 50 μM of the MAPKK MEK inhibitor PD98059 for 1 h followed by 2.5 μM WA for 6 h or 24 h. Pretreatment with the inhibitor alone resulted in increased ERK1/2 phosphorylation but limited WA-induced phosphorylation in a time-dependent manner (Fig. 4b) . Alterations in apoptosis were assessed by cleaved caspase 3 and cleaved PARP levels. WA alone induced observable caspase 3 and PARP cleavage at 24 h in both cell lines and PARP cleavage alone at 6 h in U87TMZ. However, cleaved caspase 3 and PARP levels were increased when combined with the MEK inhibitor at 24 h in U251TMZ and 6 h in U87TMZ, demonstrating that MAPK pathway activation with WA treatment appears to represent a compensatory response to the apoptotic effects induced by the compound.
Finally, the tyrosine kinase receptors EGFR, Her2/ErbB2, and c-Met, known to signal to both the Akt/mTOR and MAPK pathways, were evaluated due to their status as common amplified, mutated, and/or drug-targeted surface proteins in GBM [45] [46] [47] [48] [49] . Total levels of EGFR and Her2/ErbB2 in both U251TMZ and U87TMZ decreased with 2.5-5 μM WA treatment at 24 h and 48 h while total levels of c-Met decreased at 5 μM (Fig. 4a) . Interestingly, increased phosphorylation of Tyr1068 on EGFR was observed at 2.5-5 μM depending on the cell line as well as increased phosphorylation of Tyr1234/1235 on c-Met in U87TMZ cells up to 2.5 μM WA at 48 h. Phosphorylation of c-Met was otherwise downregulated with WA treatment in both lines.
Withaferin A elevates oxidative status and induces a heat shock stress response in TMZ-resistant cells
We have previously demonstrated the ability of WA to elevate oxidative potential and ROS-mediated cell death in TMZsensitive GBMs [34] . TMZ has also been demonstrated to produce ROS that result in inhibitory activation of AMPK [50] . We therefore evaluated the nature and ability of WA to continue to induce ROS in TMZ-resistant U87TMZ and U251TMZ cells. Peroxide-type radical production was monitored with CM-H 2 DCFDA conversion at 3 h post-WA exposure. Both cell lines showed statistically significant increased detectible CM-H 2 DCFDA fluorescence with increasing WA exposure. ROS levels rose 20.9 % (p= 0.001), 36.6 % (p =0.002), and 38.8 % (p = 0.01) in U251TMZ and 21.3 % (p=0.003), 40.6 % (p=0.004), 47.3 % (p=0.001) in U87TMZ cells at 1, 3, and 5 μM WA compared to control, respectively (Fig. 5a ). The thiol antioxidant and ROS scavenger NAC was added simultaneously with WA and was shown to nearly complete abrogate WA-generated ROS, further demonstrating the nature of the effect.
Various models of oxidative stress are known to be associated with a heat shock response via induction of several HSPs [51, 52] , and alteration of HSPs were previously reported following WA treatment [34, 53] . Treatment with WA yielded a unique pattern of HSP expression modulation in U251TMZ and U87TMZ cells (Fig. 5b) . Total levels of HSP32/heme oxygenase one and HSP70, but not HSP90, were observed to increase with increasing concentrations of WA at 24 h. HSP27 was depleted at 24 h with 5 μM WA in both cell lines but remained largely unchanged in U251TMZ and mildly elevated in U87TMZ with other concentrations at 24 h. The transcription factor heat shock factor 1 (HSF1) showed dose-dependent reduction in expression between 1 and 5 μM WA. Pretreatment with 5 mM NAC virtually eliminated all modulation of proteins in the heat shock system (Fig. 5b) .
Functionally, WA-induced depletion of ATP levels, a marker of reduced cellular viability in the CellTiter-Glo assay, could be reduced or completely eliminated with 1-5 mM NAC pretreatment (p<0.0001) (Fig. 5c) . Such effects were seen with up to 6 μM WA, the highest concentration examined. Additionally, re-evaluation of cell death by flow cytometry as previously described following pretreatment with 5 mM NAC showed the elimination of death-associated PI and Annexin V staining normally induced by 5 μM WA (p<0.01) (Fig. 5d) . This was supported by blockage of PARP cleavage via NAC pretreatment (Fig. 5b) . Additionally, WA-mediated cyclin B 1 induction was blocked by NAC, demonstrating the prevention of G2/M cell cycle arrest seen with WA treatment.
Withaferin A resensitizes TMZ-resistant GBM cells to TMZ through MGMT depletion
Expression of MGMT is associated with TMZ resistance in GBMs and therefore is an attractive target for TMZ resistance resensitization and prevention [13] . WA demonstrated the ability to induce depletion of MGMT at 48 h in cell lines (U251TMZ, T98G, and U138) utilizing MGMT as the primary means of TMZ resistance (Fig. 6a) . U251TMZ and U138 cells showed progressive depletion of MGMT from 0.5 to 10 μM WA with approximately 5-fold and 20-fold less compared to control by 5 μM, respectively. At 5 μM WA treatment, there was a 43 % reduction in MGMT in T98G cells with complete elimination by 10 μM. U87TMZ cells, however, failed to express MGMT altogether.
To determine if these findings extended to functional resensitization of resistant cells to TMZ, two cells lines resistant through MGMT (U251TMZ and T98G) and one cell line displaying MGMT-independent resistance (U87TMZ) were treated with WA for 24 h followed by TMZ and evaluated with the MTS assay (Fig. 6b) . Both U251TMZ and T98G showed statistically significant decreases in cell viability when Proteins associated with cellular stress and heat shock were evaluated by immunoblotting at 24 h and revealed elevated levels of HSP32 and HSP70, known to be upregulated in response to oxidative stress, but decreased transcription factor HSF1 with increasing WA exposure that could be completely eliminated with 5 mM NAC pretreatment. NAC also prevented induction of cyclin B 1 and cleavage of PARP. Functionally, NAC pretreatment reduced the anti-proliferative (c) and pro-cytotoxic (d) effects of WA as assessed by the CellTiter-Glo assay at 72 h and flow cytometry at 24 h, respectively. *p<0.05, **p<0.01, ***p<0.001 1, 1.5, or 2 μM WA was combined with 300 or 500 μM TMZ. Pretreatment with 2 μM WA followed by 300 μM TMZ yielded a 32 % (p<0.0001) and 34 % (p=0.004) relative decrease in U251TMZ and T98G cell viability compared to TMZ or WA alone, respectively. In contrast, U87TMZ cells only demonstrated a statistically significant enhancement of combination therapy over TMZ alone-only 6 % additional reduction in relative viability-with a 2 μM WA and 300 μM TMZ combination (p=0.02). Forty-eight hour pretreatment with WA also demonstrated enhanced effect with significant elimination of the benefit by 72 h pretreatment (data not shown). WA pretreatment did not prevent TMZ efficacy in Because TMZ also depletes MGMT [54] , the effect of WA and TMZ combination on MGMT levels was evaluated. Combination therapy demonstrated dose-dependent synergy or potentiation to reduce total levels of MGMT in U251TMZ, T98G, and U138 MGMT-expressing cells (Fig. 6c) . At 1 μM WA in U251TMZ and U138 cells and 2.5 μM WA in T98G cells, minimal decreases and/or increases of MGMT levels were observed. The addition of 300 μM TMZ for 24 h resulted in 43 %, 52 %, and 34 % reduction in MGMT protein levels compared to TMZ alone in U251TMZ, T98G, and U138 cells, respectively.
Phosphorylation of H2A.X as a marker of double strand DNA damage and cleavage of PARP during apoptosis were evaluated to look for molecular evidence of combinational efficacy. Both markers were elevated in the setting of increasing concentrations of WA in U251TMZ, T98G, U138, and U87TMZ cells. However, PARP cleavage was then diminished at the high levels of U87TMZ and U138 cells suggesting non-apoptotic cell death or very late apoptosis at this timepoint. Addition of TMZ was observed to increase p-H2A.X and PARP cleavage in only T98G, particularly at 1 μM WA. Interestingly, despite similar or increased levels of cleaved PARP within WA treatment groups, levels of uncleaved PARP increased with TMZ treatment in each of the TMZ groups but not control in U251TMZ and T98G cells. Given the reported oxidative effect induced by TMZ [50] , markers of oxidative stress including HSP32, HSP70, and p-AMPKα as well as the AMPK-influenced downstream phosphorylation of mTOR were evaluated to determine if combination of WA and TMZ demonstrated enhanced oxidative effect in GBM. While WA increased HSP32 and HSP70 levels in all lines and TMZ enhanced phosphorylation of AMPKα in U138, combination therapy did not result in additional effect and failed to further diminish mTOR activation (Online Resource 2b).
Discussion
While withaferin A has demonstrated effectiveness as a promising new therapeutic agent in a variety of cancer types including TMZ-sensitive GBM, this work is the first to explore its efficacy in a known model of drug-resistance. Here, we show for the first time that WA induces a potent cytotoxic effect against temozolomide resistant GBMs resulting in G2/ M arrest and apoptosis from both the intrinsic and extrinsic systems. These findings correspond with the elevation of cellular oxidative potential and inhibitory modulation of the Akt/mTOR pathway but not the MAPK pathway.
Since its approval by the FDA, TMZ remains the standardof-care chemotherapeutic agent in the treatment of primary GBM. Exposure to this agent results in DNA adducts such as O6-methylation of guanine which, if not removed by MGMT, can mispair with thymine. Cells with intact MMR undergo futile cycles of attempted repair with resultant replicationassociated DNA double strand breaks, G2/M arrest, and ultimately apoptosis [55] . Targeting mechanisms of DNA damage repair with various inhibitors, such as those of PARP and ataxia telangiectasia mutated (ATM), has provided potentially beneficial strategies in enhancing TMZ effect, but comparatively limited effort has gone into addressing both inherent and acquired resistance to TMZ by MGMT expression or, less frequently, MMR mutation in GBM. Despite about half of patients displaying tumor phenotypes not conducive to TMZ use, it remains a first-line agent, demonstrating the need for better tumor screening techniques. Furthermore, initially responsive tumors are often quick to develop resistance to this line of therapy [14, 15] .
Several experimental agents used to resensitize resistant cancer cells to TMZ or other alkylating agents-such as valproic acid [44, 56, 57] , O6-benzylguanine [58, 59] , IL-24 [60] , and silencing oligonucleotides [61] [62] [63] -possess little practical intrinsic anti-cancer cytotoxic properties or clinical applicability, however, some do have the potential for adverse effects in the patient. Alternatively, dose-dense TMZ scheduling, used to deplete MGMT levels quickly to enhance TMZ effects, has yielded disappointing outcomes in several clinical trials [64] . In this study, WA acted as both an inherently cytotoxic agent and an enhancer of the efficacy of TMZ in MGMT-driven resistant cell lines while maintaining TMZ sensitivity in parental lines. Such data conceptually support the utility of combination therapy WA with TMZ in the firstline treatment of GBM. Such an approach should maximize anti-cancer activity across broad tumor heterogeneity. Importantly, while tumors with resistance due to MMR mutation may not be resensitized to TMZ by WA, the presence of a second cytotoxic chemotherapeutic agent may provide significant benefit in the context of ineffective TMZ treatment. It remains to be fully explored whether increased levels of p-H2A.X observed with WA treatment are a result of direct DNA damage, perhaps through an oxidative mechanism, or rather a known byproduct observed during cellular apoptosis for DNA fragmentation [65] , however, preliminary results in breast cancer support a caspase-mediated mechanism (data not published). Elevated total PARP with increasing TMZ in the presence of WA in MGMT-expressing lines may indicate the necessity for increased base excision repair (BER) during combination therapy, alluding to induction of DNA damage as a reason for combinational efficacy which will need to be validated by further scientific investigation.
Several studies have implicated the role of WA in the disruption of HSP90 chaperone function through its binding to the C-terminus of HSP90 [26, 66] . While direct evidence of such an inhibitory effect has not yet been established, downstream depletion of various HSP90-related client proteins suggests that WA may indeed act at least in part as a novel HSP90 inhibitor. This could explain and support the wide-ranging effects observed in this study, including the depletion in total levels of known HSP90 client proteins such as Akt, mTOR, Raf-1, and EGFR. By depleting these key regulatory client proteins of HSP90, the normal signaling axes of multiple proliferative pathways are simultaneously modulated. MGMT, which is depleted in the presence of WA, has not, however, been reported as a client protein of HSP90.
Indeed, current studies demonstrate that total levels of MGMT are not impacted by the widely-utilized HSP90-inhibitor 17-AAG until high concentrations (1-2 μM) are achieved, suggesting that its stability and function are not directly maintained by HSP90 (data not shown). Santagata, et al. demonstrated the thiol reactivity of WA [19] , and our results implicate an oxidative mechanism, representing an alternative means by which MGMT and other non-HSP90 client proteins may be targeted for degradation by WA. Interestingly, valproic acid, which diminishes MGMT levels, has also been shown to cause oxidative stress in glioma cell lines [67] .
Induction of oxidation has become a promising mechanism by which to target cancer. Alterations in the redox potential of cancer cells due to various molecular turnover and quick replication results in increased cellular stress that can be exploited to shift cells into a state of cytotoxicity [68, 69] . This approach circumvents traditional therapeutic options such as antigen-targeting and DNA-damaging agents that have received the most attention but are often rendered useless due to rapid development of resistance. In GBM, such traditional agents have been explored in patients but have yielded unimpressive results in clinical trials largely due to the development of tumor mutations that limit the effectiveness and/or relevance of a particular targeted therapeutic [14, 17] .
In the present study, thiol-reactivity and oxidation by WA resulted in depletion of proteins in the Akt/mTOR and MAPK pathways including many cell surface receptors either through direct interaction or as a downstream effect of the inhibition of other proteins. As noted previously, other reports have shown additional pathways effected. Such an ability to target multiple pathways simultaneously with a single compound has great potential to generate an enhanced anti-cancer effect while reducing the development of resistance to a particular target. The ability to modulate multiple of the Akt/mTOR pathway simultaneously provides a novel and important mechanism by which WA can manifest its beneficial effects against GBMs. Because of mutations in proteins like the tumor suppressor phosphatase and tensin homolog (PTEN), this pathway is frequently overactivated in GBM to drive proliferation, as shown in both U251 and U87 cells [70] [71] [72] . Interestingly, while we previously showed WA-mediated activation of AMPKα and downstream tumor suppressor TSC2 which act to inhibit mTOR in both U251 and U87 parental cells [34] , U87TMZ appears to have lost the ability to act through this pathway which suggests direct inhibition of the Akt/mTOR axis.
WA treatment yields subsequent induction of the MAPK pathway as demonstrated by activating phosphorylation of EGFR, Raf-1, and ERK1/2. Previous studies have shown that reactive oxygen species generated by epoxide-containing compounds in GBM cells are responsible for the phosphorylation of ERK1/2 which then drives apoptosis [73] . In contrast, inhibition of this pathway prior to WA exposure yields enhanced apoptosis, suggesting that the activation of the MAPK pathway is a compensatory pro-survival response to apoptotic shifts in the cell and may be a therapeutic target that would synergistically enhance the efficacy of WA in future combinational therapy studies.
The studies presented here provide an important framework for the utilization of WA in TMZ-resistant GBM as both a monotherapy and as a resensitizer in combination with the standard chemotherapeutic agent TMZ. WA demonstrates an oxidative mechanism that leads to anti-proliferative and proapoptotic effects largely through Akt/mTOR pathway modulation. Simultaneously, depletion of MGMT allows for enhanced activity of TMZ. While future pre-clinical animal studies will be necessary to determine its translational potential in GBMs, evidence is supportive of a future clinical potential for the utilization of WA across the heterogeneic spectrum of glioma patients.
